



March 19, 2025

PeptiDream Inc
<https://www.peptidream.com>
(Securities Code: 4587 TSE Prime Market)

PeptiDream Featured in a Video Produced by the Prime Minister's Office of Japan

KANAGAWA, JAPAN – March 19, 2025 - PeptiDream Inc., a public Kanagawa, Japan-based biopharmaceutical company (Representative Director and President: Patrick C. Reid, hereinafter "PeptiDream")(Tokyo: 4587) today announced that PeptiDream was featured as a representative biotech company in Japan in a video titled "Japan: The New Land of Drug Discovery" produced by Office of Global Communications, the Prime Minister's Office of Japan.

The video was planned and produced by Office of Global Communications, the Prime Minister's Office of Japan to introduce Japan as a country of drug discovery where competitive research is being conducted, and the government provides support in various aspects. Patrick C. Reid, Representative Director and President of PeptiDream, explained that PeptiDream is one of Japan's leading biotech companies and has been a partner of choice for global pharmaceutical companies due to its competitive technology. He also mentioned that the company's expansion into the radiopharmaceuticals space has led to further growth of collaborations with partners.

The video can be viewed at the following link.

[LINK](#)

About PeptiDream Inc.

PeptiDream Inc. (Tokyo Stock Exchange Prime Section 4587) is leading the translation of macrocyclic peptides into a whole new class of innovative medicines to address unmet medical needs and improve the quality of life of patients worldwide. In its radiopharmaceutical business, through its wholly-owned subsidiary PDRadiopharma, PeptiDream markets and sells a number of approved radiopharmaceuticals and radiodiagnostics in Japan, as well as leveraging its proprietary Peptide Discovery Platform System (PDPS) technology to discover and develop a deep pipeline of innovative targeted radiotherapeutics and radiodiagnostics, spanning both wholly-owned internal programs and globally partnered programs. In its non-radiopharmaceutical business, PeptiDream is similarly leveraging PDPS to discover and develop a broad and diverse pipeline of investigational peptide therapeutics, peptide drug conjugates (PDC) and multi-functional peptide conjugates (MPC) across an extensive global network of discovery and development partners. PeptiDream is headquartered in Kawasaki, Japan. For more information about our company, science and pipeline, please visit www.peptidream.com/en/

Inquiries:

PeptiDream Inc.

Contact: Yuko Okimoto, IR & Public Affairs

Email: info@peptidream.com